Esophageal Cancer - Pipeline Review, H1 2014
2014 Jun 30
208 Pages (PDF)
Esophageal Cancer - Pipeline Review, H1 2014 Summary Global Markets Directs, Esophageal Cancer - Pipeline Review, H1 2014, provides an overview of the Esophageal Cancers therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Esophageal Cancer Overview 8 Therapeutics Development 9 Pipeline Products for Esophageal Cancer - Overview 9 Pipeline Products for Esophageal Cancer - Comparative Analysis 10 Esophageal Cancer - Therapeutics under Development by Companies 11 Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 15 Esophageal Cancer - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Esophageal Cancer - Products under Development by Companies 20 Esophageal Cancer - Products under Investigation by Universities/Institutes 22 Esophageal Cancer - Companies Involved in Therapeutics Development 23 Bristol-Myers Squibb Company 23 Boehringer Ingelheim GmbH 24 Amgen Inc. 25 GlaxoSmithKline plc 26 Gilead Sciences, Inc. 27 Daiichi Sankyo Company, Limited 28 Novartis AG 29 Ono Pharmaceutical Co., Ltd. 30 CTI BioPharma Corp. 31 Genmab A/S 32 Advaxis, Inc. 33 Immunomedics, Inc. 34 Takara Bio Inc. 35 Synta Pharmaceuticals Corp. 36 Transgene Biotek Limited 37 Supratek Pharma Inc. 38 Glycotope GmbH 39 Hutchison MediPharma Limited 40 Advantagene, Inc. 41 CerRx, Inc. 42 Cerulean Pharma, Inc. 43 MacroGenics, Inc. 44 Merrimack Pharmaceuticals, Inc. 45 Omnitura Therapeutics Inc. 46 Omeros Corporation 47 Oncolys BioPharma Inc. 48 ImmunoFrontier, Inc. 49 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 50 Mebiopharm Co., Ltd. 51 Kite Pharma, Inc. 52 Aslan Pharmaceuticals Pte. Ltd. 53 Precision Biologics, Inc. 54 Esophageal Cancer - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Combination Products 56 Assessment by Target 57 Assessment by Mechanism of Action 61 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 nimotuzumab - Drug Profile 69 paclitaxel poliglumex - Drug Profile 72 ganetespib - Drug Profile 76 varlitinib - Drug Profile 80 doxorubicin nanoformulation - Drug Profile 82 CRLX-101 - Drug Profile 84 MM-111 - Drug Profile 86 afatinib - Drug Profile 88 MBP-426 - Drug Profile 91 nivolumab - Drug Profile 93 IMF-001 - Drug Profile 97 margetuximab - Drug Profile 99 Vaccine for Oncology - Drug Profile 101 Anti-NY ESO-1 Lymphocytes Vaccine - Drug Profile 102 HLA-A2402 Restricted Epitope Peptide URLC10, CDCA1, KOC1 Vaccine - Drug Profile 103 AMG-337 - Drug Profile 104 IMMU-132 - Drug Profile 105 rhLT28-171 - Drug Profile 106 Cell Therapy Targeting NY-ESO-1 for Oncology - Drug Profile 107 fenretinide - Drug Profile 108 OBP-301 - Drug Profile 110 binimetinib - Drug Profile 111 BYL-719 - Drug Profile 115 LJM-716 - Drug Profile 117 patritumab - Drug Profile 119 HuMax-TF-ADC - Drug Profile 121 BMS-833923 - Drug Profile 122 HMPL-813 - Drug Profile 124 cetuximab biobetter - Drug Profile 125 GSK-2256098 - Drug Profile 126 TBI-1201 - Drug Profile 127 Autologous Tumor Cell Vaccine + [celecoxib] - Drug Profile 129 DKN-01 - Drug Profile 130 Recombinant Adenoviral Human p53 Gene Therapy - Drug Profile 132 OMN-54 - Drug Profile 133 ADXS-HER2 - Drug Profile 135 NEO-201 - Drug Profile 136 TBL-0805E - Drug Profile 138 Drug For Esophageal Cancer - Drug Profile 139 First Generation Attenuated Strain Of Reovirus - Drug Profile 140 rAAV-VICN003 - Drug Profile 141 1-BB1 - Drug Profile 142 Small Molecule To Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 144 Histone Demethylase Inhibitors for Esophageal Cancer - Drug Profile 145 Esophageal Cancer - Recent Pipeline Updates 146 Esophageal Cancer - Dormant Projects 194 Esophageal Cancer - Discontinued Products 195 Esophageal Cancer - Product Development Milestones 196 Featured News & Press Releases 196 Appendix 204 Methodology 204 Coverage 204 Secondary Research 204 Primary Research 204 Expert Panel Validation 204 Contact Us 205 Disclaimer 205
Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Amgen Inc. GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Limited Novartis AG Ono Pharmaceutical Co., Ltd. CTI BioPharma Corp. Genmab A/S Advaxis, Inc. Immunomedics, Inc. Takara Bio Inc. Synta Pharmaceuticals Corp. Transgene Biotek Limited Supratek Pharma Inc. Glycotope GmbH Hutchison MediPharma Limited Advantagene, Inc. CerRx, Inc. Cerulean Pharma, Inc. MacroGenics, Inc. Merrimack Pharmaceuticals, Inc. Omnitura Therapeutics Inc. Omeros Corporation Oncolys BioPharma Inc. ImmunoFrontier, Inc. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Mebiopharm Co., Ltd. Kite Pharma, Inc. Aslan Pharmaceuticals Pte. Ltd. Precision Biologics, Inc.